Biopharma firm Roivant's Q1 revenue declines, net loss widens to $273.9 mln
Overview
Roivant fiscal Q1 revenue declines significantly, reflecting increased R&D expenses
Company reports net loss from continuing operations of $273.9 mln
Roivant completed $1.5 bln share repurchase program, reducing shares by over 15%
Outlook
Roivant expects brepocitinib DM trial data in H2 2025
Company anticipates brepocitinib NIU trial results in H1 2027
Roivant plans new $500 mln share repurchase program
Company maintains cash runway into profitability
Result Drivers
R&D EXPENSES - Increased by $32.4 mln due to program-specific costs and personnel-related expenses, primarily driven by anti-FcRn franchise
SHARE REPURCHASE - Completed $1.5 bln share repurchase program, reducing shares by over 15%
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue |
| $2.17 mln |
|
Q1 EPS |
| -$0.33 |
|
Q1 Net Income |
| -$273.91 mln |
|
Q1 Income From Operations | Miss | -$284.92 mln | -$255.80 mln (4 Analysts) |
Q1 Operating Expenses |
| $287.09 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Roivant Sciences Ltd is $17.50, about 34.3% above its August 8 closing price of $11.49
Press Release: ID:nGNXbByr39
Related Articles
Investing in Healthcare Stocks
TradingKey - After a year of underperformance, the health care sector is emerging as one of the most interesting places for long-term investors looking for a mixture of resilience and innovation. The health care stocks trailed broader indexes in 2024 as money poured into AI, technology...
Seth Klarman Portfolio
TradingKey - Seth Klarman, the Baupost value investor, long had the distinction of navigating doubt with surgeon-like precision. The technique is married to asymmetric bets, deep margin-of-safety work, and, of course, in many cases, a dash of contrarian genius..jfif)
U.S. Stock Strategy: The Rapid Development of AI Signals a Promising Future
TradingKey - Since Trump announced a 90-day suspension of the "reciprocal tariffs" imposed on certain countries on 9 April this year, all three major U.S. stock indices have recorded significant gains. Looking ahead, against the backdrop of easing global trade frictions.
China July Inflation Commentary: CPI Exceeds Expectations
TradingKey - On 9 August 2025, China's National Bureau of Statistics released inflation data for July. The Consumer Price Index (CPI) rose by 0.4% month-on-month, reversing the previous month's 0.1% decline, while remaining unchanged year-on-year. Core CPI increased by 0.8% year-on-year.
U.S. CPI Preview: Bullish Outlook for U.S. Stocks Continues
TradingKey - On 12 August 2025, the U.S. will release its July CPI data. Market consensus forecasts a year-over-year headline CPI increase of 2.8% and a core CPI rise of 3%, both up 0.1 percentage points from June. We align with these widely held market expectations. Breaking it down by category...
